Announcement PDF ABN 16 165 160 841 ASX RELEASE 14 November 2024 AMPLIA ENTERS INTO PRECLINICAL COLLABORATION WITH KOREAN SPECIALIST DRUG SCREENING COMPANY NEXT&BIO HIGHLIGHTS • A preclinical research collaboration with specialist drug screening company Next & Bio has been established • The collaboration explores the effect of Amplia’s FAK inhibitors in combination with experimental drugs called kRas inhibitors • kRas inhibitors are being developed for the treatment of pancreatic cancer Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that it has entered into a research collaboration with Korean preclinical drug screening company Next&Bio. A research collaboration agreement between the companies was signed at the headquarters of Next&Bio in Seoul, Korea. Next&Bio, a wholly-owned subsidiary of healthcare conglomerate Hk Kolmar Holdings headquartered in Seoul, Korea, have developed a unique capability in drug screening. The platform capability involves the testing of drugs, both alone and in combination with approved or experimental treatments, in cancer cells isolated from patients. Importantly, the cancer cells are grown under special conditions to closely resemble the environment present in the patient’s cancer, thereby better predicting how effectively drugs will act against the cancer. In particular, Next&Bio have established these patientderived cells from pancreatic cancer patients. The research collaboration will explore the activity of Amplia’s FAK inhibitors against patient-derived pancreatic cancer cells that harbour known oncogenic mutations. These are changes to the DNA that can cause cells to become cancerous and develop into tumours. Specifically, the Company is interested in exploring potential synergistic activity of the Company’s FAK inhibitors with a new class of drugs currently in development that inhibit the potent oncogene kRas. These drugs have the potential to be used in the treatment of pancreatic cancer in coming years. The Company’s CEO and Managing Director, Dr Chris Burns, commented, “To be able to test our FAK inhibitors in these well-characterised patient-derived cell systems, gives us the chance to explore the activity of our compounds in combination with targeted therapies such as kRas inhibitors. This in turn opens up new commercial opportunities for our FAK inhibitors to be used in combination with drug classes currently in clinical development for pancreatic cancer in addition to the chemotherapy combination currently being investigated in the ACCENT trial.” This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics. About Narmafotinib Narmafotinib (AMP945) is the company’s best-in-class inhibitor of the protein FAK, a protein overexpressed in pancreatic and other cancers, and a drug target gaining increasing attention for its role in Level 17, 350 Queen Street, Melbourne VIC 3000 Email info@ampliatx.com www.ampliatx.com solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. The drug has successfully completed a healthy volunteer study and is currently in an open-label Phase 2a trial in pancreatic cancer where a combination of narmafotinib and the chemotherapies gemcitabine and Abraxane® is being assessed for safety, tolerability and efficacy. Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com About Amplia Therapeutics Limited Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163 Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx), Threads (@ampliatx) and LinkedIn.